Phathom (NASDAQ: PHAT) defends VOQUEZNA exclusivity through 2032 as BDR sues FDA
by Jessica Moore · The Cerbat GemWhat happened
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) said BDR Pharmaceuticals International Pvt. Ltd. filed suit against the FDA and related Federal Defendants on October 23, 2026. The case was filed in the United States District Court for the District of Columbia. It challenges FDA's refusal to receive an abbreviated new drug application referencing Phathom's NDA for VOQUEZNA. BDR says FDA wrongly used the GAIN Act to extend Phathom's NCE exclusivity for VOQUEZNA, or vonoprazan fumarate, tablets.
Phathom said FDA carefully and correctly handled the issue in its June 6, 2025 grant of Phathom's December 11, 2024 Citizen Petition. FDA recognized 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032. Phathom said it is reviewing the BDR filings.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Remaining NCE exclusivity from report date | 5 years 6 months 10 days | Calculated from SEC 8-K | |
| NCE exclusivity for VOQUEZNA tablets | 10 years | SEC 8-K | |
| NCE exclusivity end date | May 3, 2032 | SEC 8-K |
Read more: Phathom Pharmaceuticals (PHAT) stock analysis and investment case
Why it matters
VOQUEZNA can build value only if exclusivity and launch execution last long enough to support the branded franchise. This filing helps and hurts that view at the same time. It shows Phathom defending the exclusivity period, but it also keeps the regulatory risk in place. The report date is still about 5 years 6 months before May 3, 2032, so the protection window is still important.
That makes the filing a direct read on the franchise runway, not a new operating update.
The dispute also affects when ANDAs can be received and possibly approved. The filing says BDR may succeed in its challenge, which could shorten the exclusivity period and allow earlier ANDA review or approval. It also says the litigation, including appeals, may take a long time and be costly and distracting. The company says those developments could hurt VOQUEZNA sales, Phathom's business, and its prospects.
Earlier generic review would pressure the length of exclusivity and the timing of competition.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
Phathom says it plans to take appropriate action to protect its statutory exclusivities. The next question is whether the court upholds FDA's recognition of 10 years of NCE exclusivity through May 3, 2032 or shortens it. A ruling that keeps the end date in place would support the case. A ruling that narrows exclusivity would weaken it. May 3, 2032 is the key date to watch.
More from OptimistFi
- PHAT stock: the Phathom Pharmaceuticals thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
Sources
- SEC 8-K — Phathom announced BDR's suit against the FDA and FDA's recognition of 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032.
Read the full OptimistFi thesis on Phathom Pharmaceuticals, Inc.: https://optimistfi.com/stocks/PHAT
See what would break the Phathom Pharmaceuticals, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Phathom Pharmaceuticals, Inc. investment case, its status and the next test to watch live on the Phathom Pharmaceuticals, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.